{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:54:12Z","timestamp":1787115252063,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41433-020-01295-y","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T14:26:47Z","timestamp":1606228007000},"page":"2754-2762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma"],"prefix":"10.1038","volume":"35","author":[{"given":"Timothy T.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Deufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly S.","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","volume":"32","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363\u201372.","journal-title":"Retina"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1755-3768.1970.tb06592.x","volume":"48","author":"O Jensen","year":"1970","unstructured":"Jensen O. Malignant melanomas of the human uvea: recent follow\u2010up of cases in Denmark, 1943\u20131952. Acta Ophthalmol. 1970;48:1113\u201328.","journal-title":"Acta Ophthalmol"},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaapos.2011.10.012","volume":"16","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: Features and prognosis in 317 children and adults. J AAPOS. 2012;16:10\u20136.","journal-title":"J AAPOS"},{"key":"1295_CR4","doi-asserted-by":"crossref","unstructured":"Singh AD, Damato BE. Iris melanoma. Clinical Ophthalmic Oncology: Springer; 2019. p. 155\u201384.","DOI":"10.1007\/978-3-030-17879-6_10"},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0161-6420(00)00449-8","volume":"108","author":"CL Shields","year":"2001","unstructured":"Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001;108:172\u20138.","journal-title":"Ophthalmology"},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archophthalmol.2011.286","volume":"130","author":"S Khan","year":"2012","unstructured":"Khan S, Finger PT, Yu G-P, Razzaq L, Jager MJ, De Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130:57\u201364.","journal-title":"Arch Ophthalmol"},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2009.08.007","volume":"149","author":"BF Fernandes","year":"2010","unstructured":"Fernandes BF, Krema H, Fulda E, Pavlin CJ, Payne DG, McGowan HD, et al. Management of iris melanomas with 125Iodine plaque radiotherapy. Am J Ophthalmol. 2010;149:70\u20136. e2.","journal-title":"Am J Ophthalmol"},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1755-3768.2010.01967.x","volume":"90","author":"L Razzaq","year":"2012","unstructured":"Razzaq L, Keunen JEE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJW. Ruthenium plaque radiation therapy for iris and iridociliary melanomas. Acta Ophthalmol. 2012;90:291\u20136.","journal-title":"Acta Ophthalmol"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ophtha.2012.06.053","volume":"120","author":"CL Shields","year":"2013","unstructured":"Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L, Shields JA. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology 2013;120:55\u201361.","journal-title":"Ophthalmology"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/eye.2011.222","volume":"25","author":"M Tsimpida","year":"2011","unstructured":"Tsimpida M, Hungerford J, Arora A, Cohen V. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma. Eye. 2011;25:1607\u201311.","journal-title":"Eye"},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ijrobp.2011.09.033","volume":"83","author":"YA Yousef","year":"2012","unstructured":"Yousef YA, Finger PT. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma. Int J Radiat Oncol Biol Phys. 2012;83:1107\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/bjophthalmol-2012-302659","volume":"97","author":"L Konstantinidis","year":"2013","unstructured":"Konstantinidis L, Roberts D, Errington RD, Kacperek A, Damato B. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol. 2013;97:471\u20134.","journal-title":"Br J Ophthalmol"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bjophthalmol-2014-305174","volume":"99","author":"GD Willerding","year":"2015","unstructured":"Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, et al. Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. 2015;99:812.","journal-title":"Br J Ophthalmol"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.ijrobp.2009.12.002","volume":"78","author":"RM Thomson","year":"2010","unstructured":"Thomson RM, Furutani KM, Pulido JS, Stafford SL, Rogers DW. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:1261\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1295_CR15","doi-asserted-by":"crossref","unstructured":"Amin MB, Edge SB. AJCC cancer staging manual. Springer; 2017.","DOI":"10.1007\/978-3-319-40618-3_2"},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1118\/1.1646040","volume":"31","author":"MJ Rivard","year":"2004","unstructured":"Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31:633\u201374.","journal-title":"Med Phys"},{"key":"1295_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.survophthal.2016.12.012","volume":"62","author":"M Popovic","year":"2017","unstructured":"Popovic M, Ahmed IIK, DiGiovanni J, Shields CL. Radiotherapeutic and surgical management of iris melanoma: a review. Surv Ophthalmol. 2017;62:302\u201311.","journal-title":"Surv Ophthalmol"},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0002-9394(01)01007-8","volume":"132","author":"PT Finger","year":"2001","unstructured":"Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 2001;132:328\u201335.","journal-title":"Am J Ophthalmol"},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0002-9394(02)02241-9","volume":"135","author":"CL Shields","year":"2003","unstructured":"Shields CL, Naseripour M, Shields JA, Freire J, Cater J. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135:648\u201356.","journal-title":"Am J Ophthalmol"},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ophtha.2017.02.015","volume":"124","author":"SS Chaugule","year":"2017","unstructured":"Chaugule SS, Finger PT. Regression patterns of iris melanoma after palladium-103 ((103)Pd) plaque brachytherapy. Ophthalmology 2017;124:1023\u201330.","journal-title":"Ophthalmology"},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/bjophthalmol-2017-310278","volume":"102","author":"U Agraval","year":"2018","unstructured":"Agraval U, Sobti M, Russell HC, Lockington D, Ritchie D, Cauchi P, et al. Use of ruthenium-106 brachytherapy for iris melanoma: the Scottish experience. Br J Ophthalmol. 2018;102:74\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000493269","volume":"5","author":"W Liu","year":"2019","unstructured":"Liu W, Kim JM, Young BK, Nath R, Chen Z, Decker RH, et al. Novel eye plaque designs for brachytherapy of iris and ciliary body melanoma and the first clinical application. Ocul Oncol Pathol. 2019;5:220\u20138.","journal-title":"Ocul Oncol Pathol"},{"key":"1295_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/jcb.2011.24819","volume":"3","author":"DJ Scanderbeg","year":"2011","unstructured":"Scanderbeg DJ, Vasudev D, Rice RK, Goldbaum M, Mundt AJ. A modified COMS plaque for iris melanoma. J Contemp Brachytherapy. 2011;3:131\u20133.","journal-title":"J Contemp Brachytherapy"},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1118\/1.4749933","volume":"39","author":"S-T Chiu-Tsao","year":"2012","unstructured":"Chiu-Tsao S-T, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, et al. Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys. 2012;39:6161\u201384.","journal-title":"Med Phys"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01295-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T10:03:09Z","timestamp":1632132189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-01295-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}